The Start-Up Market at CPHI Barcelona brings together 27 start-ups, innovators, and small enterprises from across the pharma landscape.
As CPHI Barcelona approaches, the pharmaceutical world is gearing up to explore promising innovations that could shape the future of healthcare. This year is historic for CPHI, as it introduces a dedicated exhibition zone exclusively for start-ups, which are the innovation hubs of the industry. As part of its overarching mission to accelerate the journey of innovative medicines to patients worldwide, CPHI is shining a spotlight on some of the most promising early-stage technological innovations poised to impact the global pharmaceutical landscape. In this context, we had the privilege to engage with two emerging start-ups, one in the realm of devices and the other specializing in enhancing solubility, both offering unique solutions set to reshape the pharmaceutical landscape.
Read this article in the Trends in Formulation ebook.
This article was written by the CPHI Content Team.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.